HRID857760

反应详情

EQUATION

反应方程式

REACTANTS

反应物

HCID11

1,2-Dichloroethane

C2H4Cl2

HCID8471

Triethylamine

C6H15N

HCID181649

3H-1,2,3-Triazolo[4,5-b]pyridine, 3-hydroxy-

C5H4N4O

HCID21866177

未命名化合物

结构：O=C(NCc1cc(Cl)ccc1-n1cncn1)[C@@H]1CCCN1

HCID69656007

未命名化合物

PRODUCTS

生成物

结构：CC(C)C1CCN(C(=O)OC(C)(C)C)[C@@H]1C(=O)N1CCC[C@H]1C(=O)NCc1cc(Cl)ccc1-n1cncn1

HCID69655666

未命名化合物

AUXILIARIES

试剂、催化剂与溶剂

溶剂HCID6228

N,N-Dimethylformamide

C3H7NO

PROCEDURE

实验过程

A mixture of 1-(tert-butoxycarbonyl)-3-isopropyl-dl-proline, (77 mg, 0.30 mmol), N-[5-chloro-2-(1H1,2,4-triazol-1-yl)benzyl]-L-prolinamide (Example 27, Step B, 113 mg, 0.30 mmol), HOAt (20 mg, 0.15 mmol), EDC (86 mg, 0.45 mmol) and Et3N (80 μL, 0.60 mmol) in 1.5 mL DMF was stirred at room temperature. The diastereomeric products were separated by reverse phase HPLC (30 min gradient elution with 95:5 H2O/0.1% TFA:CH3CN/0.1% TFA to 5:95 H2O/0.1% TFA:CH3CN/0.1% TFA) and carried on directly to deprotection.

WORKUP

后处理

customThe diastereomeric products were separated by reverse phase HPLC (30 min gradient elution with 95:5 H2O/0.1% TFA:CH3CN/0.1% TFA to 5:95 H2O/0.1% TFA:CH3CN/0.1% TFA)

来源与证据

来源类型: Open Reaction Database
ORD 记录: ord-7c1061318f7b40258fe19787052f28e2
来源数据集: uspto-grants-2006_12
DOI: 10.6084/m9.figshare.5104873.v1
专利: US07144899B2
来源说明: uspto-grants-2006_12

反应 SMILES

[C:1]([O:5][C:6]([N:8]1[CH2:15][CH2:14][CH:13]([CH:16]([CH3:18])[CH3:17])[CH:9]1[C:10]([OH:12])=O)=[O:7])([CH3:4])([CH3:3])[CH3:2].[Cl:19][C:20]1[CH:21]=[CH:22][C:23]([N:35]2[CH:39]=[N:38][CH:37]=[N:36]2)=[C:24]([CH:34]=1)[CH2:25][NH:26][C:27](=[O:33])[C@@H:28]1[CH2:32][CH2:31][CH2:30][NH:29]1.C1C=NC2N(O)N=NC=2C=1.C(Cl)CCl.CCN(CC)CC>CN(C=O)C>[C:1]([O:5][C:6]([N:8]1[CH2:15][CH2:14][CH:13]([CH:16]([CH3:18])[CH3:17])[C@H:9]1[C:10]([N:29]1[CH2:30][CH2:31][CH2:32][C@H:28]1[C:27]([NH:26][CH2:25][C:24]1[CH:34]=[C:20]([Cl:19])[CH:21]=[CH:22][C:23]=1[N:35]1[CH:39]=[N:38][CH:37]=[N:36]1)=[O:33])=[O:12])=[O:7])([CH3:2])([CH3:3])[CH3:4]